Cell Essentials Inc

Blue Sky BioServices, founded in 2003 to serve the Boston area life sciences research hub, is the leading Contract Research Organization (CRO) providing R&D based Gene through Screen services for biotech and pharma companies from startups to established leaders in the field. Our customers enhance the quality and speed of their research by partnering with Blue Sky to receive world class services including; gene synthesis and bulk plasmid preparations, antibody cloning, scale-up production of recombinant proteins in multiple cell lines including mammalian, insect, bacterial and yeast, as well as antibody/protein purification and robust, rapid assay services such as cytotoxicity and qPCR, MSD. Our Assay team can support many commercially available screening technology in 96 and 384-well formats (fluorescent, colorimetric, etc.). Ultimately, we want to run YOUR assay, YOUR way. We will build out additional capabilities and capacity to support your screening workflow.

Blue Sky differentiates itself with its team of experienced scientists, leading edge process technology, and state-of-the-art laboratory facilities. Our commitment to scientific expertise and value has transformed the company into a center of excellence with unmatched quality and turnaround times.

We are motivated by ensuring our customers have an excellent experience working with Blue Sky. We do that by delivering projects on time, with high quality, at competitive prices, led by our team of highly skilled, energetic and collaborative scientists.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 100 patents and over 270 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide. GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

AcZon is an Italian Company specializing in biotechnology that develops, produces and commercializes Silica Nanoparticles (Nanoprobes) - for diagnostic, clinical and research fields- as well as a range of conventional reagents optimized for various applications as, for example, fluorescent antibodies. People’s Health is the main focus and ultimate goal of our business; our “mission” is basically “To promote and providing Reagents for Diagnostics and Research, with very high brilliance and clarity of image, stability and sensitivity, by offering products and services that speed-up the diagnostic response time, provide a better service to the patient”. AcZon focuses with growing interest on the amazing potentials offered by combining chemistry, biotechnology and nanotechnology. Indeed, on this basis, AcZon has developed and optimized a line of new products (reagents for in vitro diagnostics and research) characterized by outstanding performances. Thanks to its team of researchers (chemists and biologists), all with considerable experience in the synthesis and functionalization of polymers and in the fields of immunology, proteins and bio-conjugations, AcZon has developed, and is now producing, a line of NanoProbes (proprietary technology), based on Silica NanoParticles (NPs), which are not exclusively suitable for diagnostic and clinical applications, but also for chemistry, pharmacy, agriculture and the environment

ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release'​ technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release'​ platform drives value through better products delivered with greater efficiency.

In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.

For more information on our services and Lock Release please visit

www.adcbio.com

AltaBioscience is recognised worldwide as a leading manufacturing and analysis laboratory providing synthesis of DNA and peptides and analysis of proteins and other biochemical molecules, to researchers in academia, pharmaceuticals and the food industry.

Certified to ISO/IEC 17025:2005 for amino acid analysis, protein sequencing and steroid analysis. ISO 9001:2008 for the laboratory as a whole, AltaBioscience is committed to supplying high-quality products and analytical services at competitive prices.

• Custom Peptide Synthesis
• Tags & Conjugations
• Amino Acid Analysis
• N-Terminal Edman Protein Sequencing
• DNA/Oligo Synthesis
• Custom Antibody Generation
• Circular Dichroism analysis
• HPLC and MS Analytical Testing